AstraZeneca, Eli Lilly and Sinopharm all achieved exits as the cancer therapy developer listed on the Hong Kong Stock Exchange at a reported valuation of nearly $1.1bn.

Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.

The cancer drug developer has closed an initial public offering which took place alongside a $160m SoftBank-led private placement.

Canon, Kansai Electric Power, Mitsui Fudosan, NEC, NTT Docomo, So-net and T-Gaia were among the investors that scored exits as the CCTV system provider went public.

SoftBank invested $125m through a $160m private placement as portfolio company and cancer drug developer Exscientia went public in an offering sized at nearly $305m.

Tencent, Nikon, Amgen and Illumina all scored exits as the DNA sequencing provider's shares popped in the wake of its flotation.

The American Express-backed eyewear retailer's market capitalisation exceeded $6.1bn in the wake of its direct listing on the New York Stock Exchange.

The GV-backed restaurant organisation platform developer has issued $130m in additional shares to close its IPO and has a market capitalisation above $28bn.

The Baidu Capital and Intuitive Surgical-backed lung disease-focused medical devices developer’s Hong Kong offering valued it at about $1.3bn.

The Johnson and Johnson, Dentsu and Koch Industries-backed diagnostics device developer priced its initial public offering in the middle of its range.